Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Overview

NASDAQ:PYXS - US7473241013 - Common Stock

1.91 USD
+0.08 (+4.37%)
Last: 9/10/2025, 1:43:58 PM

PYXS Key Statistics, Chart & Performance

Key Statistics
52 Week High5.39
52 Week Low0.83
Market Cap118.46M
Shares62.02M
Float47.51M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.25
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO10-08 2021-10-08
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PYXS short term performance overview.The bars show the price performance of PYXS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

PYXS long term performance overview.The bars show the price performance of PYXS in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PYXS is 1.91 USD. In the past month the price increased by 75.96%. In the past year, price decreased by -51.59%.

PYXIS ONCOLOGY INC / PYXS Daily stock chart

PYXS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.85 371.38B
AMGN AMGEN INC 12.7 149.10B
GILD GILEAD SCIENCES INC 14.86 142.74B
VRTX VERTEX PHARMACEUTICALS INC 23.04 100.07B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 61.71B
REGN REGENERON PHARMACEUTICALS 12.21 59.07B
ARGX ARGENX SE - ADR 82.65 46.89B
ONC BEONE MEDICINES LTD-ADR 5.47 37.20B
INSM INSMED INC N/A 30.55B
BNTX BIONTECH SE-ADR N/A 24.24B
NTRA NATERA INC N/A 23.20B
BIIB BIOGEN INC 8.86 20.79B

About PYXS

Company Profile

PYXS logo image Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Company Info

PYXIS ONCOLOGY INC

321 Harrison Avenue

Boston MASSACHUSETTS US

Employees: 44

PYXS Company Website

PYXS Investor Relations

Phone: 16172219059

PYXIS ONCOLOGY INC / PYXS FAQ

What is the stock price of PYXIS ONCOLOGY INC today?

The current stock price of PYXS is 1.91 USD. The price increased by 4.37% in the last trading session.


What is the ticker symbol for PYXIS ONCOLOGY INC stock?

The exchange symbol of PYXIS ONCOLOGY INC is PYXS and it is listed on the Nasdaq exchange.


On which exchange is PYXS stock listed?

PYXS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PYXIS ONCOLOGY INC stock?

13 analysts have analysed PYXS and the average price target is 6.32 USD. This implies a price increase of 231.1% is expected in the next year compared to the current price of 1.91. Check the PYXIS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PYXIS ONCOLOGY INC worth?

PYXIS ONCOLOGY INC (PYXS) has a market capitalization of 118.46M USD. This makes PYXS a Micro Cap stock.


How many employees does PYXIS ONCOLOGY INC have?

PYXIS ONCOLOGY INC (PYXS) currently has 44 employees.


What are the support and resistance levels for PYXIS ONCOLOGY INC (PYXS) stock?

PYXIS ONCOLOGY INC (PYXS) has a support level at 1.38 and a resistance level at 1.91. Check the full technical report for a detailed analysis of PYXS support and resistance levels.


Is PYXIS ONCOLOGY INC (PYXS) expected to grow?

The Revenue of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -79.35% in the next year. Check the estimates tab for more information on the PYXS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PYXIS ONCOLOGY INC (PYXS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PYXIS ONCOLOGY INC (PYXS) stock pay dividends?

PYXS does not pay a dividend.


When does PYXIS ONCOLOGY INC (PYXS) report earnings?

PYXIS ONCOLOGY INC (PYXS) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of PYXIS ONCOLOGY INC (PYXS)?

PYXIS ONCOLOGY INC (PYXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).


What is the Short Interest ratio of PYXIS ONCOLOGY INC (PYXS) stock?

The outstanding short interest for PYXIS ONCOLOGY INC (PYXS) is 10.59% of its float. Check the ownership tab for more information on the PYXS short interest.


PYXS Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to PYXS. When comparing the yearly performance of all stocks, PYXS is a bad performer in the overall market: 64.54% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PYXS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PYXS. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PYXS Financial Highlights

Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -0.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -78.14%
ROE -109.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-3.45%
Sales Q2Q%N/A
EPS 1Y (TTM)-0.81%
Revenue 1Y (TTM)-82.53%

PYXS Forecast & Estimates

13 analysts have analysed PYXS and the average price target is 6.32 USD. This implies a price increase of 231.1% is expected in the next year compared to the current price of 1.91.

For the next year, analysts expect an EPS growth of -39.94% and a revenue growth -79.35% for PYXS


Analysts
Analysts84.62
Price Target6.32 (230.89%)
EPS Next Y-39.94%
Revenue Next Year-79.35%

PYXS Ownership

Ownership
Inst Owners40.18%
Ins Owners5.7%
Short Float %10.59%
Short Ratio9.09